BRISTOL MYERS SQUIBB CO (BMY) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$61.10

From 52W high−12.25%

Volume12.79M

Market cap$122.05B

P/E (TTM)13.2x

P/S (TTM)2.5x

Div yield4.22%

Key dataOct 16, 2026

Open

$61.10

From 52W high

−12.25%

Volume

12.79M

Market cap

$122.05B

ValuationView details →

P/E (Fwd)

9.3x

EV/EBITDA

9.2x

P/E (TTM)

13.2x

RSI (14)

47.3

MomentumView details →

1D Return

−1.35%

YTD Return

+12.28%

SummaryUpdated Jun 1, 2026

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company founded in 1887 and headquartered in New York. The company was formed through the merger of Bristol-Myers Company and Squibb Corporation, with Bristol-Myers Company tracing its origins to the Clinton Pharmaceutical Company established by William McLaren Bristol and John Ripley Myers. Today, Bristol-Myers Squibb stands as one of the world's leading pharmaceutical companies, focusing on discovering, developing, and commercializing innovative medicines for serious diseases including cancer, cardiovascular conditions, immunological disorders, and neurological conditions.

Ask drillr about BRISTOL MYERS SQUIBB CO →

ValuationView details →

P/E (Fwd)

9.3x

P/E (TTM)

13.2x

EV/EBITDA

9.2x

EV/Sales

3.1x

P/S (TTM)

2.5x

P/B (TTM)

5.5x

ProfitabilityView details →

Gross Margin

70.16%

Net Margin

18.87%

EBITDA Margin

34.19%

ROE (TTM)

41.59%

ROA (TTM)

10.59%

Asset Turnover

0.57x

GrowthView details →

Revenue YoY

+3.11%

EPS YoY

+82.66%

FCF YoY

−21.53%

Revenue CAGR 3Y

+1.45%

EPS CAGR 3Y

+5.22%

EBITDA YoY

+11.59%

MomentumView details →

1D Return

−1.35%

YTD Return

+12.28%

1Y Return

+38.82%

RSI (14)

47.3

vs 50D SMA

−4.66%

vs 200D SMA

+1.54%

Capital & dividendView details →

Debt/Equity

1.93x

Current Ratio

1.53x

Quick Ratio

1.38x

Div Yield

4.22%

Div Rate

$2.52

Div Growth 1Y

+1.61%

EarningsView details →

EPS (Actual)

$2.04

EPS Surprise

28.14%

Beats (12Q)

11/12

Next Q EPS Est

$1.61

Avg Surprise (4Q)

12.27%

Rev Surprise

10.16%

Financials snapshotView financials →

Revenue (TTM)

49.19B

Net Income (TTM)

9.28B

Op. CF (TTM)

12.78B

Next earningsOct 29, 2026 →

Latest newsMore news →

The listed top gainers included Perrigo, up 3.77%; GILEAD SCIENCES, INC., up 3.8%; Kroger, up 3.87%; BRISTOL MYERS SQUIBB CO, up 4.61%; and UNITEDHEALTH GROUP INC, up 4.73%.2d ago

BRISTOL MYERS SQUIBB CO reported mixed Phase III trial results for admilparant in idiopathic pulmonary fibrosis and positive results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors.3d ago

Similar companies

CSPC Pharmaceutical Group Limited01093.HK GSK plcGSK SanofiSNY Pfizer Inc.PFE Novo Nordisk A/SNVO Gilead Sciences, Inc.GILD Find similar companies →

Latest newsMore news →

The listed top gainers included Perrigo, up 3.77%; GILEAD SCIENCES, INC., up 3.8%; Kroger, up 3.87%; BRISTOL MYERS SQUIBB CO, up 4.61%; and UNITEDHEALTH GROUP INC, up 4.73%.2d ago BRISTOL MYERS SQUIBB CO reported mixed Phase III trial results for admilparant in idiopathic pulmonary fibrosis and positive results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors.3d ago BRISTOL MYERS SQUIBB CO reported that its Phase III ALOFT-IPF trial of admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.4d ago